anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Percutaneous coronary intervention (PCI) patients combined with thrombocytopenia (TP) are usually considered to be at low ischemic risk, receiving less proper antiplatelet therapy. However, recent studies reported a paradoxical phenomenon that PCI patients with TP were prone to experience thrombotic events, while the mechanisms and future treatment remain unclear. We aim to investigate whether inflammation modifies platelet reactivity among these patients. Consecutive 10 724 patients undergoing PCI in Fuwai Hospital were enrolled throughout 2013. High-sensitivity C-reactive protein (hsCRP) ≥2 mg/L was considered inflammatory status. TP was defined as platelet count <150×109/L. High on-treatment platelet reactivity (HTPR) was defined as adenosine diphosphate-induced platelet maximum amplitude of thromboelastogram >47mm. Among 6617 patients finally included, 879 (13.3%) presented with TP. Multivariate logistic regression demonstrated that patients with TP were associated with a lower risk of HTPR (odds ratio [OR] 0.64, 95% confidence interval [CI] 0.53-0.76) than those without TP in the overall cohort. In further analysis, among hsCRP <2 mg/L group, patients with TP exhibited a decreased risk of HTPR (OR 0.53, 95% CI 0.41-0.68); however, in hsCRP ≥2mg/L group, TP patients had a similar risk of HTPR as those without TP (OR 0.83, 95% CI 0.63-1.08). Additionally, these results remain consistent across subgroups, including patients presenting with acute coronary syndrome and chronic coronary syndrome. Inflammation modified the platelet reactivity of PCI patients with TP, providing new insights into the mechanisms of the increased thrombotic risk. Future management for this special population should pay more attention to inflammation status and timely adjustment of antiplatelet therapy in TP patients with inflammation.
Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
An extrusion system that is operable to facilitate the extrusion of a solution through manipulation of a first syringe and a second syringe. The extrusion system includes a tubing network wherein the tubing network includes a first portion coupled to a first port of an extrusion cartridge and a second portion coupled to a second portion of an extrusion cartridge. The first portion of the tubing network includes an inlet line having an inlet valve coupled therewith and a first syringe. A purge line and purge line clamp are further included in the first portion. The second portion includes a second syringe, an exit line and an exit line clamp. The extrusion system utilizes reciprocating movements of the plungers of the first syringe and second syringe to facilitate the passing of the solution through the extrusion cartridge.
Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
The title vaccines, which are for the control of respiratory infections caused by bovine Adenovirus, contain as active ingredient a thermosensitive strain of bovine Adenovirus having a "cut off" temp. of 39-40 degrees C. It is prepd. from a pathogenic strain of bovine Adenovirus by contacting the virus and an aq. buffered soln. of HNO2 at room temp. and pH 4.2-5, and isolating by at least one passage in limited dilution through a tissue culture known to permit growth of the Adenovirus, and suitable as a substrate for vaccine prepns. a thermosensitive mutant strain of bovine Adenovirus having a "cut off" temp. of 39-40 degrees C. The HNO2 soln. is pref. buffered with acetate, and the thermosensitive virus strain is pref. bovine Adenovirus 3 "Eunice". The vaccine is non-pathogenic.
An injectable intraocular sustained-release antiviral drug and a manufacturing method and application thereof. The antiviral drug is an insoluble phosphonoformate salt microcrystal. The insoluble phosphonoformate salt is a multivalent metal salt of phosphonoformic acid. The manufacturing method comprises: reacting a monovalent metal salt of phosphonoformic acid with a soluble multivalent metal salt in water; and obtaining a system containing the insoluble phosphonoformate salt microcrystal. An insoluble phosphonoformate salt microcrystal sustained release system is designed and developed to meet special needs of a sustained and controlled release intraocular injection. The nominal drug loading of the system is higher than 100%. The insoluble phosphonoformate salt microcrystal sustained-release antiviral can be released sustainably and stably in a vitreous chamber of a rabbit eye. The vitreous concentration of phosphonoformate continuously remains higher than an effective therapeutic concentration of sodium phosphonoformate. The antiviral drug has a sustained release period of up to 12 weeks and does not induce significant toxic or inflammatory reactions. The insoluble phosphonoformate salt can be used as an antiviral drug suitable for sustained release intravitreal injection technology.
The study will include 25 non-IBD age and sex-matched controls to compare data alongside the CD patients. These patients will be undergoing routine colonoscopy as per their normal colon screening routine, with this study not requiring additional scheduling commitments. Blood, mucosal washing, and intestinal biopsy samples will be collected during routine colonoscopy procedure. The patient will have the option to send in their stool sample one week prior to their day of colonoscopy or two weeks after their scoping.
PURPOSE: To obtain a new substance having inhibitory action on interleukin I production, useful as a therapeutic agent for rheumatoid arthritis, gout, osteoporosis and atherosclerosis and showing antimicrobial activity and useful as an antimicrobial agent. CONSTITUTION: A physiologically active substance of the formula (R is 4- methyl-1-pentenyl, 3-methyl-1-pentenyl or 1-methylpentene) such as E1-1511-3 wherein R is 4-methyl-1-pentenyl. Properties: yellow powder. Melting point: 165-168 deg.C. Solubility: readily soluble in dimethyl sulfoxide and acetone and soluble in methanol. Color reaction: positive in iodine and sulfuric acid. The substance is obtained by culturing a bacterium [preferably Streptomyces sp. E-1511 (FERM BP-4,792)] belonging to the genus Streptomyces, capable of producing the compound of the formula and collecting the substance from the culture product.
Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
The present invention pertains to a novel magnesium-serinate compound and a use thereof, and more specifically, to: a novel magnesium-serinate compound in which magnesium atoms are chelate-bonded to L-serine; and a pharmaceutical use thereof related to central nervous system diseases, etc. A novel magnesium-serinate compound obtained from the production method of the present invention was found to consist of about 10% of magnesium and about 90% of serine on the basis of instrumental analysis results. The compound was found to be soluble in room temperature water at a concentration of about 500 mg/ml within a pH range of 6.0-10.0 and remain in an aqueous solution state without sedimentation, was found to be soluble at a concentration of about 500 mg/ml without sedimentation even in a physiological saline (phosphate-buffered saline, PBS) solution at room temperature, and was thus confirmed to have properties suitable as an orally administrable and injectable substance to the human body. The compound activated mitochondrial function and neuronal cell proliferation by improving the mitochondrial oxygen consumption rate, exhibited a neuroprotective effect of inhibiting oxidative stress-induced mitochondrial membrane potential damage and/or endoplasmic reticulum stress-induced neuronal cell death, and exhibited improved vascular-brain barrier permeability. Thus, the compound is very effective in preventing, treating, and alleviating central nervous system diseases such as cognitive disorders, intellectual disorders, microencephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile-X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Therefore, the present invention is very useful for the pharmaceutical industry, etc.
The human scalp and face define two important body units, both functionally and aesthetically. Traumatic deformities of the head and neck region resulting from burn injuries, gun shot wounds, or ablative tumor surgeries may involve the defect of the skin, subcutaneous tissue, muscle or the combination of all these elements. In most cases, the ideal reconstruction is very difficult to achieve. Sometimes, a major part of face along with the ear or the nose may be involved. The extensive scalp loss due to burn or avulsion injury is another deforming and psychologically debilitating condition presenting as a major reconstructive challenge. An ideal reconstructive procedure should replace the missing tissues and restore the motor and sensory function. Traditional reconstructive procedures of facial deformities involve skin grafting, local flap applications, tissue expansion, and prefabrication as well as free tissue transfers. The primary goal during facial reconstruction is restoration of the function and aesthetic appearance. To obtain satisfactory results, missing parts should be replaced only by tissues of the same color and texture. The purpose of this study is to apply human facial allograft transplant to the subjects with severe facial deformities or disfigurements in order to provide adequate coverage, aesthetic appearance and functional outcome.
The present invention relates to compositions and methods for providing mitochondria-selective targeting agents covalently linked to desired cargo such as radical scavenging agents. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using specific structural signaling features recognizable by cells as mitochondrial targeting sequences are discussed. A method for delivering these agents effectively into cells and mitochondria where they act as electron scavengers by way of certain targeting sequences is also disclosed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels. In further preferred embodiments, the composition for scavenging radicals in a mitochondrial membrane includes a radical scavenging agent and a membrane active compound having a high affinity with said mitochondrial membrane and associated methods. In another embodiment, the cargo transported by mitochondrial-selective targeting agents may include an inhibitor of nitrous oxide system (NOS) enzyme activity.
Patients with diabetes exhibit an increased risk for the development of cardiovascular disease with a significantly impaired prognosis compared to patients without diabetes. Recent data from the EMPA-REG Outcome Trial suggest that treatment with the SGLT-2 inhibitor Empagliflozin reduces cardiovascular events, cardiovascular mortality as well as hospitalization for heart failure in patients with type 2 diabetes and pre-existing cardiovascular disease. Empagliflozin leads to reduction of blood glucose by an increased glucose excretion reduces blood pressure and weight. Still, it remains unclear how empagliflozin led to this pronounced reduction of cardiovascular mortality the EMPA-REG OUTCOME trial. Thus, our registry will analyse various biochemical as well as clinical markers in patients with type 2 diabetes and newly initiated treatment with empagliflozin. and an indication for intensification of glucose lowering therapy with empagliflozin. Patients with an indication for an intensified glucose-lowering therapy (HbA1c \> 7,5%) will receive 10 mg empagliflozin and we will perform biochemical analyses of blood samples including insulin, glucagon as well as metabolites at baseline as well as after 1 and 6 months. In addition we will assess echocardiographical data.
Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by inhibiting the 11-beta-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH) production by the pituitary. With continued blockade of the enzymatic steps leading to production of cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH release, and a corresponding elevation of these steroids in the plasma and of their metabolites in the urine. These metabolites are readily determined by measuring urinary 17‑hydroxycorticosteroids (17-OHCS) or 17-ketogenic steroids (17-KGS). Because of these actions, Metopirone is used as a diagnostic test, with urinary 17-OHCS measured as an index of pituitary ACTH responsiveness. Metopirone may also suppress biosynthesis of aldosterone, resulting in a mild natriuresis.
The digital prehabilitation programme comprises three 35-minute exercise sessions per week, including a warm-up, vigorous intensity aerobic and resistance exercises, and breathing exercises. The digital prehabilitation programme will be tailored to the participant's mobility level and fitness level, which will be assessed via in-platform questionnaires and functional assessments. Functional assessments will be repeated every two weeks to adapt the prehabilitation programme according to changes in fitness level. Within PreActiv's website, participants will be enrolled into a managed community forum of patients and healthcare professionals where they can post their achievements and questions. Alongside access to PreActiv's digital prehabilitation, patients will be given educational materials that summarise the benefits of prehabilitation and how to realise them.
Patients with longstanding T1DM and \<20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
A composition comprising pseudoceramide stabilized by nanoliposome is provided to show improved skin permeation property and skin moisturizing property and improve functions of the skin by comprising extracts of Physeolus radiatus and Sophora flavescens with excellent anti-inflammatory and antibacterial effects, thereby being effective for improving and alleviating atopic dermatitis. A cosmetic composition for improving and alleviating atopic dermatitis comprises extracts of Physeolus radiatus and Sophora flavescens stabilized in nanoliposome comprising pseudoceramide represented by the formula(1) as an effective ingredient. In the formula(1), in case of Y is HN(C=O)R, Z is OH, and X is OH, O(P=O)(OH)2 or O(SO2)OH; and in case of Z is HN(C=O)R, Y is OH, and X is OH, O(P=O)(OH)2 or O(SO2)OH, wherein R is C1-40 saturated or unsaturated linear or branched aliphatic hydrocarbon, provided that R has at least one OH if it is substituted. Regarding the total weight of the composition, 0.1-20.0 wt.% of the nanoliposome is contained. Regarding the total weight of the nanoliposome, 0.001-40 wt.% of each of the extracts of Physeolus radiatus and Sophora flavescens is contained. Further, the cosmetic composition is solution, suspension, emulsion, paste, gel, cream, lotion, powder or oil.
Automatically gathering and processing data relating to risk of patient falls. The data is analyzed to determine a level of risk each patient has for falling. Patient risk for falls is stratified and protocols are implemented to mitigate that risk. The system communicates instructions and alerts to caregivers to complete tasks or provide aid to patients. Updates to patient medical information and updates to best practices in fall risk management result in updates to patient risk stratifications. In turn, tasks and alerts are updated to reflect updates to patient risk stratifications.
The same therapist for the ROC-Stand(2-hr) group will be responsible for the program. The training frequency and guidelines are the same as the ROC-Stand(2-hr) group, except for the training intensity of 1-hour per session and intervention duration for 24 weeks. Each 1-hour session will include a 35-minute car play and a 25-minute natural play. The participants will also wear the head-mounted eye tracker in one training session for recording 20 minutes (the first 10-minute of driving and the first 10-minute of natural play) every week.
Oxcarbazepine is an antiepileptic drug available as 300 mg/5 mL (60 mg/mL) oral suspension. Oxcarbazepine is 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide, and its structural formula is:

Oxcarbazepine, USP is a white to faintly orange crystalline powder. It is slightly soluble in chloroform, dichloromethane, acetone, and methanol and practically insoluble in ethanol, ether and water. Its molecular weight is 252.27.

Oxcarbazepine oral suspension, USP contains the following inactive ingredients: colloidal silicon dioxide, malic acid, methylparaben, polyethylene glycol, pregelatinized starch (maize), propyl paraben, propylene glycol, purified water, saccharin sodium, sodium benzoate, sorbitol, xanthan gum and yellow plum lemon flavor. Hydrochloric acid solution or sodium hydroxide solution may be added for adjustment of pH.
Malnutrition can have significant negative effects on older people's health, as well as a cost burden for health and social care services. Accurate, reliable and regular measurement of a patient's weight is important for prompt identification and management of malnutrition. This article discusses a quality improvement project that was undertaken in an emergency assessment unit for patients aged over 74 years in Northern Ireland. The aim of the project was to improve completion of Malnutrition Universal Screening Tool (MUST) scores for patients attending the unit by nursing staff recording actual weight rather than recalled weight. A simple intervention of relocating weighing scales in the unit's triage bay resulted in an increase in completed MUST scores from 60% ( n =18) to 97% ( n =29) in the six months following the intervention. Feedback from members of the multidisciplinary team indicated that the intervention had a positive effect on the care they provided to patients and on their working relationships with colleagues.
This is a cross-sectional survey. The normal physical examination population is divided into three groups,including premenopausal nullipara, premenopausal women with childbirth and postmenopausal women. The pelvic floor muscle function in three groups are evaluated. The modified Oxford Grading Scale and Levator ani testing is used to quantify PFM strength through vaginal palpation. Pelvic floor muscle strength ,endurance, repetition,vaginal contraction pressure and the knack test are evaluated using a PHENIX USB 8 neuromuscular stimulation therapy system (Company: Vivaltis-Electronic Concept Lignon Innovation, Montpellier, France). In six different regions of China according to geographic region (northwest, southwest, north, east, northeast, and central-south China) , 1 or more hospitals in each area are selected as sub-centers, which needs to complete the evaluation of pelvic floor muscle function of 360 cases in 3 groups totally.
FIELD: medicine, phthisiology. SUBSTANCE: the present innovation deals with treating pulmonary tuberculosis with multiple destructions and chronic bronchitis. For this purpose, at the background of laser impact and antibacterial therapy a patient should be introduced with the tincture of phytospecies consisting of wild rosemary, plantain and thyme flowers, leaves of nettle, valerian and black currant, calendula flowers and dandelion root at certain quantitative ratio. The present method enables to shorten therapy terms, favors the resolution of inflammatory infiltration in lungs and elimination of bacterioreleasing due to complex impact upon patient's body. EFFECT: higher efficiency of therapy. 1 ex
Patients are 18 years old or older. Patients are scheduled for tumor surgery in the abdominal/pelvic area and navigation surgery with a scheduled Cone Beam CT-scan in the operating room. Patients provide written 'informed consent'. The to be administered intervention is a percutaneous tracked ultrasound measurement of the patient's pelvic bone on the operating room after anesthesia.
World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients causing detrimental effects on cardiovascular outcomes being anxiety as one of the first responses to chest pain and hospital admission causing tachycardia. This study is designed to achieve the goals of lowering the heart using the anxiolytic property of alprazolam. This randomized, parallel group, close label, placebo-controlled, event driven, interventional clinical superiority study will be conducted in Cardiology department of Shaikh Zayed Hospital with a sample size of 48 allocating using lottery method in both experimental and control group. Heart Rate at baseline and after 6 hours will be monitored in both groups to establish the fall of heart rate in both patients. Data will be collected by using pre-designed performa and will be entered and analyzed via SAS 9.4. Statistical analysis will be done using T-test and p value \<0.05 will be considered significant.

Significance of the study is to lower the required dosage of beta-blockers in order to achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.